Texas SB 2308: Relating to the establishment of a consortium to conduct United States Food and Drug Administration's drug development clinical trials with ibogaine to secure the administration's approval of the medication's use for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy and to the administration of that treatment.

Status: Effective immediately (as of 2025-06-11)

State: Texas · Session: 89R · Bill: SB 2308

Subjects: Alcoholism & Drug Abuse (I0030), Education--Higher--Institutions & Programs (I0223), HEALTH & HUMAN SERVICES COMMISSION (V0177), Health Care Providers (I0387), MEDICINE & PRESCRIPTION DRUGS (S7338), Mental Health & Substance Abuse (I0019), RESEARCH & DEVELOPMENT (S0135), State Finances--Management & Control (I0748)

Sponsors: Harris, Leach, Orr, Parker, Phelan, VanDeaver, Alders, Barry, Bell, Keith, Blanco, Buckley, Cain, Davis, Aicha, Eckhardt, Gerdes, Gámez, Hefner, LaHood, Lalani, Leo Wilson, Lopez, Janie, Lujan, McLaughlin, Metcalf, Miles

View Texas SB 2308 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.